A new study has found that the drug bevacizumab offers no survival benefits for patients with newly diagnosed glioblastoma or brain tumor. "The results of this study are counter to most expectations," said Dr. Brachman, Director of Radiation Oncology at Barrow and St. Joseph's. "Bevacizumab had been shown in earlier studies to be an effective drug in the treatment of patients with recurrent disease. But, on newly diagnosed patients, it did not, in fact, prolong ...
Read MoreYou have just read an article categorized health
titled Bevacizumab Does Not Offer Survival Benefits in Newly Diagnosed Glioblastoma Patients.
Written by:
editor - Friday, February 28, 2014
There are currently no comments for "Bevacizumab Does Not Offer Survival Benefits in Newly Diagnosed Glioblastoma Patients"
Post a Comment